Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS 2015 Feb 20;29(4):411-20
Date
01/21/2015Pubmed ID
25602681Pubmed Central ID
PMC4385712DOI
10.1097/QAD.0000000000000572Scopus ID
2-s2.0-84922400998 (requires institutional sign-in at Scopus site) 42 CitationsAbstract
OBJECTIVE: The eradication of HIV necessitates elimination of the HIV latent reservoir. Identifying host determinants governing latency and reservoir size in the setting of antiretroviral therapy (ART) is an important step in developing strategies to cure HIV infection. We sought to determine the impact of cell-intrinsic immunity on the HIV latent reservoir.
DESIGN: We investigated the relevance of a comprehensive panel of established anti-HIV-1 host restriction factors to multiple established virologic and immunologic measures of viral persistence in HIV-1-infected, ART-suppressed individuals.
METHODS: We measured the mRNA expression of 42 anti-HIV-1 host restriction factors, levels of cell-associated HIV-1 RNA, levels of total pol and 2-long terminal repeat (2-LTR) circle HIV-1 DNA and immunophenotypes of CD4 T cells in 72 HIV-1-infected individuals on suppressive ART (23 individuals initiated ART less than 1 year post-infection, and 49 individuals initiated ART greater than 1 year post-infection). Correlations were analysed using nonparametric tests.
RESULTS: The enhanced expression of a few select host restriction factors, p21, schlafen 11 and PAF1, was strongly associated with reduced CD4 T-cell associated HIV RNA during ART (P < 0.001). In addition, our data suggested that ART perturbs the regulatory relationship between CD4 T-cell activation and restriction factor expression. Lastly, cell-intrinsic immune responses were significantly enhanced in individuals who initiated ART during early versus chronic infection and may contribute to the reduced reservoir size observed in these individuals.
CONCLUSION: Intrinsic immune responses modulate HIV persistence during suppressive ART and may be manipulated to enhance the efficacy of ART and promote viral eradication through reversal of latency in vivo.
Author List
Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SKAuthor
Leslie Cockerham MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Anti-HIV AgentsCD4-Positive T-Lymphocytes
HIV Infections
HIV-1
Host-Pathogen Interactions
Humans
Immunity, Cellular
Immunophenotyping
Lymphocyte Activation
RNA, Viral
Viral Load
Virus Latency
